We measured the effect of treatment of traumatic brain injury (TBI) in the rat with human umbilical cord blood (HUCB) administered IV. HUCB cells were injected into the tail vein 24 h after TBI and the rats were sacrificed at day 28 after the treatment. The Rotarod test and the neurological severity score (NSS) were used to evaluate neurological function. The distribution of the donor cells in the brain, heart, lung, kidney, liver, spleen, bone marrow, and muscle were analyzed in recipient rats using immunohistochemical staining and laser confocal microscopy. HUCB cells injected IV significantly reduced motor and neurological deficits compared with control groups by day 28 after the treatment. The cells preferentially entered the brain and migrated into the parenchyma of the injured brain and expressed the neuronal markers, NeuN and MAP-2, and the astrocytic marker, GFAP. Some HUCB cells integrated into the vascular walls within the boundary zone of the injured area. Our data suggest that IV administration of HUCB may be useful in the treatment of TBI.
INTRODUCTION
banking has developed worldwide (15). Cord blood banking has several advantages, including availability of this source of stem cells and low viral infection rate at birth. Traumatic brain injury (TBI) continues to be an important cause of human morbidity with nearly 500,000
Another advantage is a low risk of acute graft-versushost disease, even with some degree of HLA mismatch new cases in the US annually. As many as 50,000 people are killed and an equal number disabled by TBI each (9). It has been well known that cord blood contains hematopoietic progenitor cells (24) , endothelial progeni-year (1). Despite much research and multiple studies, no therapeutic intervention has been found to be effective tor cells (19) , mesenchymal progenitor cells (11), autoimmune T cells (12), mononuclear cells (5), mast cells in promoting restitution of functional deficits after TBI. Neural transplantation has been used to treat the central (25) , and megakaryocyte progenitor cells (18) . Thus, cord blood administration may be used to treat life-nervous system diseases, including TBI, stroke, and neurodegenerative disorders (3). A major limitation in car-threatening diseases ranging from the hematopoietic system to the nonhematopoietic system (e.g., brain trauma). rying out neural transplantation has been the limited availability of donor tissues and ethical problems associ-Recently, human umbilical cord blood (HUCB) has been used to treat a mouse model (SOD-1 Knock out) of amyo-ated with the use of embryonic cells.
"Cord blood" is the blood that remains in the umbili-trophic lateral sclerosis (10). Large doses of HUCB cells (3.4-3.5 × 10 7 ) produced considerable delay in onset of cal cord and placenta after birth. Umbilical cord blood (UCB) is a plentiful and rich source of stem cells that symptoms and death of the SOD-1 mice. More than 1500 cord blood transplants in humans have been re-can be used to treat a variety of life-threatening diseases including leukemia, other cancers, and blood and im-ported worldwide but, to our knowledge, there is no report that IV administration of HUCB was attempted to mune disorders (13). Because the number of pluripotent stem cells contained in one sample of cord blood is suf-treat TBI in humans and animals. Therefore, using a controlled cortical impact (CCI) ficient for engrafting into children and adults, cord blood 276 LU ET AL. model of TBI in the rat, we tested the hypothesis that heparinized saline followed by 10% buffered formalin. The brains, hearts, lungs, livers, kidneys, spleens, mus-HUCB administration reduces injury and improves functional outcome after TBI.
cle, and bone marrow were removed and stored in 10% buffered formalin for 24 h. Seven 2-mm-thick blocks MATERIALS AND METHODS were cut on a rodent brain matrix and then embedded All experimental procedures were approved by the with paraffin. Blocks (2 mm thick) of the other organs Care of Experimental Animals Committee of Henry were also cut and embedded with paraffin. A series of Ford Hospital. adjacent 6-µm-thick sections was cut and a section of each block of the brain and other organs was stained Preparation of HUCB for Injection with H&E for morphological analysis under light mi-The HUCB used was a gift from Cryocell Internacroscopy. tional, Inc. (3165 McMullen Dr., Blvd. 3, Clearwater, Vibratome Sections. An additional four rats from each FL 33761). The specimen ID number is 19 and the specgroup received the IV administration of 1 ml of saline imen was analyzed on June 27, 2000. The specimen was containing fluorescein isothiocyanate (FITC)-dextran stored in liquid nitrogen and the cells were restored at (50 mg/ml, 2 × l0 6 molecular weight; Sigma, St. Louis, 37°C. After centrifugation at 1000 rpm/min for 10 min MO). This dye circulated for 1-2 min, after which the at 4°C, the supernatant was removed and the cells were anesthetized rats were killed by decapitation. The brains washed twice with 0.1 M PBS. Cell suspension (30 µl)
were rapidly removed from severed heads and placed in was mixed with 30 µl of 0.4 % trypan blue stain and the 4% paraformaldehyde at 4°C for 48 h. Coronal sections number of the viable cells was counted with a hemacy-(100 µm) were cut on a vibratome. tometer and a counter under a phase contrast microscope. The total number of the harvested cells was cal-Immunohistochemistry culated and the final dilution was 2 × 10 6 cells in 300 µl
Single staining was performed for identification of saline.
HUCB cells using a primary mouse anti-human nuclei monoclonal antibody (MAB 1281), specific for all hu-Controlled Cortical Injury Animal Model man cell types, and secondary Cy5-conjugated F(ab′)2 and the Injection of HUCB fragment rabbit anti-mouse IgG in the coronal sections Wistar rats were anesthetized with 350 mg/kg body of all organs. Double staining was also performed on weight chloral hydrate, IP. Rectal temperature was concoronal cerebral sections. Brains sections were initially trolled at 37°C with a feedback-regulated water-heating stained for neuronal markers, NeuN and MAP-2, or an pad. A controlled cortical impact device was used to astrocytic marker, glial fibrillary acidic protein (GFAP), induce the injury. Rats were placed in a stereotactic with the corresponding primary antibodies and the secframe. Two 10-mm-diameter craniotomies were perondary FITC-conjugated F(ab′)2 fragment, and subseformed adjacent to the central suture, midway between quently double stained with primary MAB 1281 antilamda and bregma. The second craniotomy allowed for body and second antibodies of Cy5-conjugated-F(ab′)2 movement of cortical tissue laterally. The dura was kept fragment for identification of HUCB cells. Briefly, 6intact over the cortex. Injury was induced by impacting cm-thick sections from TBI, TBI + saline, and TBI + the left cortex (ipsilateral cortex) with a pneumatic pis-HUCB groups were deparaffinized and the sections were ton containing a 6-mm-diameter tip at a rate of 4 m/s put in boiling citrate buffer (pH 6) in a microwave oven and 2.5 mm of compression. Velocity was measured for 10 min for identification of neurons. After cooling at with a linear velocity displacement transducer (7, 20) . room temperature, the sections were incubated in 0.1% Twenty-four rats subjected to TBI were divided into saponin-PBS at 4°C overnight for mAb NeuN (dilution three groups. Experimental group (n = 8): 24 h after 1:400, Chemicon) and MAP-2 (dilution 1:400, Chemi-TBI, rats were slowly injected over a 10-min duration con). Antimouse FITC-conjugated F(ab′)2 fragment (diwith 2 × 10 6 HUCB cells in 300 µl saline via a tail vein. lution 1:20, Calbiochem, CA) was then added and incu-Placebo control group (n = 8): 24 h after TBI, rats were bated for 1 week. To identify astrocytes, the sections slowly injected over a 10-min duration with 300 µl sawere treated with 0.1% pepsin 37°C for 15 min and then line via a tail vein. TBI-only group (n = 8): the rats only pAb GFAP (dilution 1:400, Dakopatts) was added. The were subjected to TBI and no treatment. All rats were sections were incubated with anti-rabbit FITC-conjukilled 28 days after the treatment. gated F(ab′)2 fragment (dilution 1:20, Calbiochem, CA) Tissue Preparation for 1 week. The above sections stained with FITC-conjugated F(ab′)2 fragment were subsequently processed for Paraffin Sections. Four animals from each group were euthanized with an overdose of ketamine and xy-identification of a human cellular nuclei antigen with a primary mouse anti-human nuclei monoclonal antibody, lazine administered IP and perfused with intracardiac MAB 1281 (dilution 1:200) and a Cy5-conjugated F(ab′)2 off the rod, a plate tripped and a liquid crystal recorded the endurance time in seconds. All rats were pretrained fragment rabbit anti-mouse IgG (dilution 1:20). The slides were analyzed using a fluorescent microscope (Olym-with five trials (warm-up trials) performed daily for 3 days prior to TBI to ensure stable baselines (14). After pus, BH-2). Because the primary antibodies used against MAB 1281, NeuN, and MAP-2 were monoclonal antibod-TBI and TBI following administration of HUCB or saline, the rats were tested on days 1, 4, 7, 14, and 28 until ies, nonspecific positive reaction could occur in double labeling staining. Therefore, a series of negative controls sacrifice. The motor test data are shown as a percentage of an average of five trials on the Rotarod test compared was used to assess and evaluate the immunohistochemical staining results. Negative control sections from each with the internal baseline values. Twenty-four hours after TBI or administration of animal received identical staining preparation, except that the primary antibodies or the secondary antibodies HUCB or saline, all rats were evaluated using the neurological severity scores (NSS) (23) . NSS is a composite were omitted.
of the motor (muscle status, abnormal movement), sen-Three-Dimensional Image Acquisition sory (visual, tactile, and proprioceptive), and reflex tests. In order to observe the relation of the donor's cells One point was given for failure to perform a task. Thus, with the cerebral vessels, the vibratome sections were the higher score, the more severe the injury, with a maxanalyzed with a Bio-Rad (Cambridge, MA) MRC 1024 imum of 14 points. Rats were reevaluated on days 1, 4, (argon and krypton) laser-scanning confocal imaging 7, 14, and 28 after the treatment. All measurements were system mounted onto a Zeiss microscope (Bio-Rad).
performed by observers blinded to individual treatment. With the FITC-perfused tissue samples from each group, Statistical Analysis 10 vibratome sections from interaural 6.38 mm to inter-NSS and Rotarod test scores were measured before aural 1.0 mm (Paxinos and Watson, 1986) at 2-mm ininjury and at 1, 4, 7, 14, and 28 days after TBI. The terval were screened at 488 nm under a 10× objective numbers of MAB 1281-reactive cells were counted at lens. Sections stained with the MAB 1281 antibody 28 days after treatment. The analysis of covariance for (Cy5) were excited by a laser beam at 647 nm (27) .
ANOVA (repeated measures) was conducted to test the Estimates of Cell Number treatment by time interactions, and the effect of treatment over time. The same analysis approach was used For measurement of MAB 1281-reactive cells, an avto analyze the outcome of Rotarod test score. Paired t-test erage number of five equally spaced slides (approxiwas used to test the difference in means of cell counts mately 100-µm interval) was obtained from each brain between the injured hemisphere and the control hemiblock and MAB 1281-reactive cells were counted within sphere. the seven 2-mm-thick blocks encompassing the forebrain. Nine slides from each of these blocks were first RESULTS stained with FITC staining for identification of NeuN (3 Histological Analysis of Organs slides), MAP-2 (3 slides), and GFAP (3 slides), and were followed by Cy5 staining for identification of HUCB Sections from the blocks of brain and organs were cells. The number of the MAB 1281-reactive cells exstained with H&E staining for the general histopathologpressing NeuN, MAP-2, and GFAP was counted, respecical evaluation. The architectural integrity of all organs tively, using fluorescent microscopy within all seven analyzed under light microscopy was not disrupted exblocks. In order to reduce biases introduced by sampling cept for the initial mechanical injury of the brain. Bleedparameters, all sections for MAB 1281 identification ing, invasion of white cells, inflammatory response, and from rats were stained simultaneously. The criteria for neoplasm were not observed on any slides aside from MAB 1281-positive cells were defined before the cells the brain. were counted by observers blinded to the individual Distribution of MAB 1281-Positive Cells treatment. All MAB 1281-reactive cells were counted throughout the coronal sections.
No MAB 1281-positive cells were observed in the slides from only TBI and TBI + saline groups, which did Neurological Functional Evaluation not receive the injection of HUCB cells. Large numbers of MAB 1281-positive cells were found in the vessels Neurological motor measurement was performed using an accelerating Rotarod motor test. The rats were of the brain, heart, lung, liver, kidney, spleen, muscle, and even bone marrow of the rats receiving the injection placed on the accelerating Rotarod treadmill (Lab-line Instruments, Inc.) and the rat's task was to walk and of HUCB. A few scattered MAB 1281-positive cells were found in the parenchyma of these organs. In the maintain its equilibrium on the rotating rod, which rotated at a gradually increasing speed. When the rat fell brain, MAB 1281-labeled cells were observed in the boundary zone of the injured area, cortex, striatum, and These double-labeled cells were observed only in the ipsilateral hemispheres of the rats in the HUCB-treated corpus callosum of the ipsilateral hemisphere. The MAB 1281-positive signals were detected in the nuclei of the group. Most of these positive cells were located in the boundary zone of the injured area: 6.9 ± 1.3% of MAB capillary endothelial cells surrounding the injured area. Using laser confocal microscopy, the implanted cells 1281-labeled cells in the ipsilateral hemispheres in the HUCB-treated group expressed NeuN, 5.8 ± 2.4% ex-were confirmed to be integrated into sprouting vessels in the boundary zone of the injured area ( Fig. 1g-i) . The pressed MAP-2, and 9.7 ± 2.8% expressed GFAP. These data demonstrate that some implanted cells express neu-total number of MAB 1281-positive cells migrating into the parenchyma of both the ipsilateral and contralateral ronal and astrocytic phenotypes. hemispheres of the brain was counted and analyzed in Neurological and Motor Function Evaluation the TBI + HUCB group. The numbers of MAB 1281-Two days after TBI, significantly lower scores of the positive cells in the ipsilateral hemisphere (43,597 ± Rotarod test and significantly higher scores of NSS in 4265) were significantly greater than those in the contrathree groups compared with preinjury were found. Rolateral hemisphere (13,742 ± 6471, p < 0.05). The data tarod test scores were significantly improved in the TBI + indicate that HUCB cells delivered to the brain via an HUCB group (138.0 ± 11.3% and 155.2 ± 16.2%) when IV route preferably migrate into the injured brain tissue.
compared with the TBI group (118.5 ± 17.0% and 129.2 ± Phenotypical Identification 12.2%) and TBI + saline group (117.2 ± 13.6% and 133.2 ± of MAB 1281-Reactive Cells 10.7%) (p < 0.05) at days 14 and 28 after administration of HUCB. The neurological severity scores were also Double fluorescent staining showed that some MAB 1281-positive cells expressed neuronal markers, NeuN significantly improved in the TBI + HUCB group (4.2 ± 1.3 and 3 ± 0.8) when compared with the TBI group (7.5 ± and MAP-2, and an astrocytic marker, GFAP (Fig. 1a-f ). 1.73 and 6.3 ± 1.3) and the TBI + saline group (7.3 ± 0.9 and 5.75 ± 0.9) (p < 0.05) at days 14 and 28 after injection. The results indicate that IV administration of HUCB 24 h after TBI reduces the motor neurological functional deficits caused by TBI (Figs. 2 and 3) .
DISCUSSION
Our major findings in this study were: 1) HUCB cells injected IV enter the brain by day 28 after HUCB cell administration; 2) IV injection of HUCB reduces motor and neurological deficits by days 14 and 28 after administration; 3) the cells migrating into the parenchyma of the brain express the neuronal markers, NeuN and MAP-2, and the astrocytic marker, GFAP; 4) HUCB cells integrated into the vascular wall within target organs; 5) these cells are also present in other organs and primarily localize to the vessels, without any obvious adverse effects. Our data suggest that IV administration of HUCB cells may be useful in the treatment of TBI. our study was designed to measure the effect of HUCB administered IV on TBI, the numbers of HUCB cells (MAB 1281-positive cells) present in the cerebral parcontralateral hemisphere. This indicates that the injected enchyma were counted and analyzed in the TBI + cells preferably migrate into the injured hemisphere, es-HUCB group. Significantly more MAB 1281-positive pecially to the boundary zone of the injured area after cells were found in the ipsilateral hemisphere than in the TBI. Nearly all of the MAB 1281-positive cells expressing NeuN, MAP-2, and GFAP were located in the ipsilateral hemisphere, demonstrating that the microenvironment of the brain after injury may drive HUCB cells into a neural cell phenotype. The mechanisms responsible for MSC engrafting into the brain remain unclear. HUCB cells may enter the brain from blood-brain barrier disruption or in response to signals from cytokines and cell surface receptors and antigens (11, 16, 25) . HUCB cells significantly increase in the presence of 24-h-old ischemia brain tissue extracts (4). These data demonstrate that the injured brain tissues secrete factors that induce the migration of HUCB cells into the brain. Brain injury also activates an enzymatic cascade of matrix metalloproteinases (MMPs) that are responsible for degradation of extracellular matrix proteins such as collagen, proteoglycan, and laminin (22) . In the central nervous system, endothelial cells, microglia, and astrocytes express MMPs in response to injury that facilitate cell migration (22) . The observation that the injected cells appear to integrate into the vascular structures surrounding the injured area suggests that the IV-injected HUCB cells may be involved in the angiogenesis of the cerebral vessels after pothesis is supported by data in which locally trans-planted endothelial precursor cells (EPCs) isolated from injected cells enter the brain, migrate into the injured area, and a few express the neuronal and astrocytic phe-umbilical cord blood into the ischemic tissues of immunodeficient nude rats survived and participated in build-notypes and integrate into the vascular structures. Cord blood administration may be a useful treatment for trau-ing capillary network (19) . Our study in treatment of brain ischemia with HUCB showed that HUCB cells in-matic brain injury. tegrated with vascular structure and expressed the endo-ACKNOWLEDGMENTS: This work was funded by Saneron thelial cell marker, Factor VIII (4). brain through different mechanisms except the replace-
